Nanoparticles in the treatment and diagnosis of neurological disorders: Untamed dragon with fire power to heal

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 8, Issue 4, 2012, Pages 399-414

  Kanwar, Jagat R ^a   Sun, Xueying ^b,c   Punj, Vasu ^d   Sriramoju, Bhasker ^a   Mohan, Rajiv R ^e   Zhou, Shu Feng ^f   Chauhan, Ashok ^g   Kanwar, Rupinder K ^a  

^a DEAKIN UNIVERSITY   (Australia)

^b THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^c THE UNIVERSITY OF AUCKLAND   (New Zealand)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF MISSOURI   (United States)

^f UNIVERSITY OF SOUTH FLORIDA   (United States)

^g UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Blood brain barrier; Nanoparticles; Neurological diseases

Indexed keywords

BLOOD-BRAIN BARRIER; DELIVERY METHODS; DELIVERY SYSTEMS; DIAGNOSTIC METHODS; FIRE POWER; MULTIPLE SCLEROSIS; NEUROLOGICAL DISEASE; NEUROLOGICAL DISORDERS; THERAPEUTIC MODALITY;

BIOCHEMISTRY; BIOINFORMATICS; BLOOD; DRUG DELIVERY; MEDICAL NANOTECHNOLOGY; NANOPARTICLES;

DIAGNOSIS;

BROMOCRIPTINE; CARBON NANOFIBER; CARBON NANOTUBE; CLIOQUINOL; CURCUMIN; GEMCITABINE; HORSERADISH PEROXIDASE; INDOMETACIN; LEUCINE ENKEPHALIN[2 DEXTRO ALANINE 6 ARGININE]; LOPERAMIDE; NANOCAPSULE; NANOPARTICLE; NANOSPHERE; OLIGONUCLEOTIDE; PACLITAXEL; PENICILLAMINE; PHOSPHOLIPID; POLYSORBATE 80; PULLULAN; QUINOLINE; RITONAVIR; RIVASTIGMINE; STREPTAVIDIN; TACRINE; TRISTEARIN;

ALZHEIMER DISEASE; BIOINFORMATICS; BLOOD BRAIN BARRIER; BRAIN CANCER; CENTRAL NERVOUS SYSTEM DISEASE; DEGENERATIVE DISEASE; DIABETIC RETINOPATHY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; GENE THERAPY; GENOMICS; GLAUCOMA; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MICELLE; MULTIPLE SCLEROSIS; NANOMEDICINE; NEUROLOGIC DISEASE; PARKINSON DISEASE; PHOTOTHERAPY; REVIEW; TISSUE ENGINEERING;

ANIMALS; BLOOD-BRAIN BARRIER; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; NERVOUS SYSTEM DISEASES;

EID: 84860255699     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2011.08.006     Document Type: Review

References (136)

1. Riggs J.E. Age specific rate of neurological disease. Neurobiol Aging 2001, 1:3-11.
2. Calvo P., Gouritin B., Villarroya H., Eclancher F., Giannavola C., Klein C., et al. Quantification and localisation of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rat. Eur J Neurosci 2002, 15:1317-1326.
3. Boado R.J. Antisense drug delivery through the blood brain barrier. Adv Drug Deliv Rev 1995, 15:73-107.
4. D'Aquino R. Fulfilling the promise of nanomedicine. Chem Eng Prog 2006, 102:35.
5. Modi G., Pillay V., Choonara Y.E., Ndesendo V.M.K., Du Toit L.C., Naidoo D. Nanotechnological applications for the treatment of neurodegenerative disorders. Prog Neurobiol 2009, 88:272-285.
6. Van Kasertan S.I., Campbell S.J., Serres S., Anthony D.C., Sibson N.R., Davis B.G. Glyconanoparticles allow pre-symptomatic in-vivo imaging of brain disease. Proc Natl Acad Sci USA 2009, 106:18-23.
7. Roney C., Kulkarni P., Arora V., Antich P., Bonte F., Wu A., et al. Targeted nanoparticles for delivery through blood brain barrier for Alzheimer's disease. J Control Release 2005, 108:193-214.
8. Jones A.R., Shusta E.V. Blood brain barrier transport of therapeutics via receptor-mediation. Pharm Res 2007, 24:1759-1771.
9. Lu W., Zhang Y., Tan Y.Z., Hu K.L., Jiang X.G., Fu S.K. Cationic albumin conjugated pegylated nanoparticles as novel drug carrier for brain delivery. J Control Release 2005, 107:428-448.
10. Baratchi S., Kanwar R.K., Khoshmanesh K., Vasu P., Ashok C., Hittu M., et al. Promises of nanotechnology in drug delivery to brain in neurodegenerative diseases. Curr Nanosci 2008, 4:1-11.
11. Townsend S.A., Evrony G.D., Gu F.X., Schulz M.P., Brown R.H., Langer R. Tetanus toxin C fragment-conjugated nanoparticles for targeted delivery to neurons. Biomaterials 2007, 28:5176-5184.
12. Hu K., Li J., Shen Y., Lu W., Gao X., Zhang Q., et al. Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations. J Control Release 2009, 134:55-61.
13. Cui Z., Lockman P.R., Atwood C.S., Hsu C.H., Gupte A., Allen D.D., et al. Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's disease and other CNS diseases. Eur J Pharm Biopharm 2005, 59:263-272.
14. Xie Y.L., Lu W., Jiang X.G. Improvement of cationic albumin conjugated pegylated nanoparticles holding NC-1900, a vasopressin fragment analog, in memory deficits induced by scopolamine in mice. Behav Brain Res 2006, 173:76-84.
15. Nowacek A., Kosloski L.M., Gendelman H.E. Neurodegenerative disorders and nanoformulated drug development. Nanomedicine (Lond.). 2009, 4:541-555.
16. Swartz R.H., Black S.E., St George-Hyslop P. Apolipoprotein E and Alzheimer's disease: a genetic, molecular and neuroimaging review. Can J Neurol Sci. 1999, 26:77-88.
17. Cummings J.L., Vinters H.V., Cole G.M., Khachaturian Z.S. Alzheimer's disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurology 1998, 51:S2-17.
18. Imbimbo B.P., Lombard J., Pomara N. Pathophysiology of Alzheimer's disease. Neuroimaging Clin N Am 2005, 15:727-753.
19. Benzi G., Moretti A. Are reactive oxygen species involved in Alzheimer's disease?. Neurobiol Aging 1995, 16:661-674.
20. Zigmond M.J., Burke R.E. Pathophysiology of Parkinson's disease. Neuropsychopharmacology-the fifth generation of progress 2002, 1781-1784. American College of Neuropsychopharmacology, Brentwood, Tennessee, Chap. 123. 5th ed. K.L. Davis, D. Charney, J.T. Coyle, C. Nemeroff (Eds.).
21. Moore D.J., West A.B., Dawson V.L., Dawson T.M. Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 2005, 28:57-87.
22. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
23. Van Duijn C.M., Dekker M.C., Bonifati V., Galjaard R.J., Houwing-Duistermaat J.J. Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. Am J Hum Genet 2001, 69:629-634.
24. Valente E.M., Abou-Sleiman P.M., Caputo V., Muqit M.M., Harvey K. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004, 304:1158-1160.
25. Compston A., Coles A. Multiple sclerosis. Lancet 2002, 359:1221-1231.
26. Kaul M., Zheng J., Okamoto S., Gendelman H.E., Lipton S.A. HIV-1 infection and AIDS: consequences for the central nervous system. Cell Death Differ 2005, 12:878-892.
27. Rao K.S., Reddy M.K., Horning J.L., Labhasetwar V. TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs. Biomaterials 2008, 29:4429-4438.
28. Huff J.S. Brain neoplasms [monograph on the Internet] Available from:. http://emedicine.medscape.com/article/779664-overview.
29. Juillerat-Jeanneret L. The targeted delivery of cancer drugs across the blood brain barrier: chemical modifications of drugs or drug-nanoparticles?. Drug Discov Today 2008, 13:1099-1106.
30. Goldbrunner R.H., Bernstein J.J., Tonn J.C. Cell-extracellular matrix interaction in glioma invasion. Acta Neurochir (Wien) 1999, 141:295-305.
31. Pepper M.S., Wasi S., Ferrara N., Orci L., Montessano R. In vitro angiogenic and proteolytic properties of bovine lymphatic endothelial cells. Exp Cell Res 1994, 210:298-305.
32. Gupta N., Yucel Y.H. Glaucoma as a neurodegenerative disease. Curr Opin Ophthalmol 2007, 18:110-114.
33. Pharmacists' Coffee Magazine Latanoprost [monograph on the Internet; posted by PCM 21 Sept 2010] Available from:. http://www.pcm.me/xalatan/.
34. Cheung N., Mitchell P., Wong T.Y. Diabetic retinopathy. Lancet 2010, 376:124-136.
35. Kreuter J. Application of nanoparticles for the delivery of drugs to the brain. Int Cong Ser 2005, 1277:85-94.
36. Huo J. A perspective on bioconjugated nanoparticles and quantum dots. Colloids Surf B Biointerfaces 2007, 59:1-10.
37. Su W.H., Suslick K.S., Stucky G.D., Suh Y.H. Nanotechnology, nanotoxicology and neuroscience. Prog Neurobiol 2009, 87:133-170.
38. Wilson B., Samanta M.K., Santhi K., Kumar K.P.S., Paramakrishnan N., Shuresh B. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease. Brain Res 2008, 1200:159-168.
39. Fischer H., Gottschlich R., Seelig A. Blood-brain barrier permeation:molecular parameters governing passive diffusion. J Membr Biol 1998, 165:201-211.
40. Ikumi Tamai A.T. Transporter-mediated permeation of drugs across the blood-brain barrier. J Pharm Sci 2000, 89:1371-1388.
41. Witt K.A., Huber J.D., Egleton R.D., Davis T.P. Insulin enhancement of opioid peptide transport across the blood-brain barrier and assessment of analgesic effect. J Pharmacol Exp Ther 2000, 295:972-978.
42. Fiori A., Cardelli P., Negri L., Savi M.R., Strom R., Erspamer V. Deltorphin transport across the blood brain barrier. Proc Natl Acad Sci USA 1997, 94:9469-9474.
43. Tabernero A., Velasco A., Granda B., Lavado E.M., Medina J.M. Transcytosis of albumin in astrocytes activates the sterol regulatory element-binding protein-1, which promotes the synthesis of the neurotrophic factor oleic acid. J Biol Chem 2002, 277:4240-4246.
44. Kumagai A.K., Eisenberg J.B., Pardridge W.M. Absorptive-mediated endocytosis of cationized albumin and a beta-endorphin-cationized albumin chimeric peptide by isolated brain capillaries. Model system of blood-brain barrier transport. J Biol Chem 1987, 262:15214-15219.
45. Dos Santos W., Rahman J., Klein N., Male D. Distribution and analysis of surface charge on brain endothelium in vitro and in situ. Acta Neuropathol 1995, 90:305-311.
46. Seferos D.S., Giljohann D.A., Rosi N.L., Mirkin C.A. Locked nucleic acid-nanoparticle conjugates. Chembiochem 2007, 8:1230-1232.
47. Bhaskar S., Tian F., Stoeger T., Kreyling W., De la Fuente J.M., Grazú V., et al. Multifunctional nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging. Part Fibre Toxicol 2010, 7:1-25.
48. Ulbrich K., Hekmatara T., Herbert E., Kreuter J. Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur J Pharm Biopharm 2009, 71:251-256.
49. Ay I., Francis J.W., Brown R.H. VEGF increases blood-brain barrier permeability to Evans blue dye and tetanus toxin fragment C but not adeno-associated virus in ALS mice. Brain Res 2008, 1234:198-205.
50. Michaelis K., Hoffmann M.M., Dreis S., Herbert E., Alyautdin R.N., Michaelis M., et al. Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain. J Pharmacol Exp Ther 2006, 317:1246-1253.
51. Narushima I., Kita T., Kubo K., Yonetani Y., Momochi C., Yoshikawa I., et al. Highly enhanced permeability of blood-brain barrier induced by repeated administration of endothelin-1 in dogs and rats. Pharmacol Toxicol 2003, 92:21-26.
52. Gaillard P.J., Brink A., De Boer A.G. Diphtheria toxin receptor-targeted brain drug delivery. Int Congr Series 2005, 1277:185-198.
53. Lu C., Pelech S., Zhang H., Bond J., Spach K., Noubade R., et al. Pertussis toxin induces angiogenesis in brain microvascular endothelial cells. Neurosci Res 2008, 86:2624-2640.
54. Xin H., Jiang X., Gu J., Sha X., Chen L., Law K., et al. Angiopep-conjugated poly(ethylene glycol)-co-poly(e-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma. Biomaterials 2011, 32:4293-4305.
55. Modi G., Pillay V., Choonara Y.E. Advances in the treatment of neurodegenerative disorders employing nanotechnology. Ann NY Acad Sci 2010, 1184:154-172.
56. Behan N., Birkinshaw C., Clarke N. Poly n-butyl cyanoacrylate nanoparticles: a mechanistic study of polymerization and particle formation. Biomaterials 2001, 22:1335-1344.
57. Bernardi A., Frozza R.L., Horn A.P., Campos M.M., Calixto J.B., Salbego C., et al. Protective effects of indomethacin-loaded nanocapsules against oxygen-glucose deprivation in organotypic hippocampal slice cultures: involvement of neuroinflammation. Neurochemistry Int 2010, 57:629-636.
58. Reis C.P., Neufeld R.J., Ribeiro A.J., Veiga F. Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomed Nanotechnol Biol Med 2006, 2:8-21.
59. Kumar R.M., Sameti M., Kneuer C., Lamprecht A., Lehr C.M. Polymeric nanoparticles for drug and gene delivery. Encyclopedia of nanoscience & nanotechnology 2003, 1-19. American Scientific Publishers, Valencia (Calif). H.S. Nalwa (Ed.).
60. Patravale V.B., Date A.A., Kulkarni R.M. Nanosuspensions: a promising drug delivery strategy. J Pharm Pharmacol 2004, 56:827-840.
61. Vinogradov S.V., Zeman A.D., Batrakova E.V., Kabanov A.V. Polyplex nanogel formulations for drug delivery of cytotoxic nucleoside analogs. J Control Release 2005, 107:143-157.
62. Bronich T.K., Bontha S., Shlyakhtenko L.S., Bromberg L., Hatton T.A., Kabanov A.V. Template-assisted synthesis of nanogels from Pluronic modified poly(acrylic acid). J Drug Target 2006, 14:357-366.
63. Vinogradov S.V., Batrakova E.V., Kabanov A.V. Nanogels for oligonucleotide delivery to the brain. Bioconjug Chem 2004, 15:50-60.
64. Kateb B., Yamamoto V., Alizadeh D., Zhang L., Manohara H.M., Bronikowski M.J., et al. Multi-walled carbon nanotube (MWCNT) synthesis, preparation, labeling, and functionalization. Methods Mol Biol 2010, 651:307-317.
65. Matsumoto K., Sato C., Naka Y., Whitby R., Shimizu N. Stimulation of neuronal neurite outgrowth using functionalized carbon nanotubes. Nanotechnology 2010, 21:1-7.
66. McKenzie J.L., Waid M.C., Shi R., Webster T.J. Decreased functions of astrocytes on carbon nanofiber materials. Biomaterials 2004, 25:1309-1317.
67. Du Toit L.C., Pillay V., Choonara Y.E., Pillay S., Harilall S.L. Patenting of nanopharmaceuticals in drug delivery: no small issue. Recent Pat Drug Deliv Formul 2007, 1:131-142.
68. Yang Z., Zhang Y., Yang Y., Sun L., Han D., Li H., et al. Pharmacological and toxicological target organelles and safe use of single-walled carbon nanotubes as drug carriers in treating Alzheimer disease. Nanomed Nanotechnol Biol Med 2010, 6:427-441.
69. Nguyen H.K., Lemieux P., Vinogradov S.V., Gebhart C.L., Guérin N., Paradis G., et al. Evaluation of polyether-polyethyleneimine graft copolymers as gene transfer agents. Gene Ther 2000, 7:126-138.
70. Harada-Shiba M., Yamauchi K., Harada A., Takamisawa I., Shimokado K., Kataoka K. Polyion complex micelles as vectors in gene therapy pharmacokinetics 2002. Gene Ther 2002, 9:407-414.
71. Pai A.S., Rubinstein I., Onyuksel H. PEGylated phospholipid nanomicelles interact with β-amyloid(1-42) and mitigate its β-sheet formation, aggregation and neurotoxicity in vitro. Peptides 2006, 27:2858-2866.
72. Torchilin V.P. Micellar nanocarriers: pharmaceutical perspectives. Pharm Res 2007, 24:1-16.
73. Voinea M., Simionescu M. Designing of 'intelligent' liposomes for efficient delivery of drugs. J Cell Mol Med 2002, 6:465-474.
74. Mora M., Sagrista M.L., Trombetta D., Bonina F.P., De Pasquale A., Saija A. Design and characterization of liposomes containing long chain N-acylPEs for brain delivery: penetration of liposomes incorporating GM1 into the rat brain. Pharm Res 2002, 19:1430-1438.
75. Mourtas S., Canovi M., Zona C., Aurilia D., Niarakis A., La Ferla B. Curcumin-decorated nanoliposomes with very high affinity for amyloid-β1-42 peptide. Biomaterials 2011, 32:1635-1645.
76. Cherney R.A., Atwood C.S., Xilinas M.E., Gray D.N., Jones W.D., McLean C.A. Treatment with a copper-zinc chelator markedly and rigidly inhibits B-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001, 30:665-676.
77. Li J., Ng H.T., Chen H. Carbon nanotubes and nanowires for biological sensing. Protein nanotechnology protocols, instrumentation, and applications. Methods in molecular biology. Vol. 300 2005, 191-223. Humana Press, Totowa (N.J.). Vo-Dinh (Ed.).
78. Sun W., Xie C., Wang H., Hu Y. Specific role of polysorbate coating on the targeting of nanoparticles to the brain. Biomaterials 2004, 25:3065-3071.
79. Wilson B., Samanta M.K., Santhi K., Kumar K.P.S., Paramakrishnan N., Suresh B. Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles. Eur J Pharm Biopharm 2008, 70:75-84.
80. Triulzi R.C., Dai Q., Zou J., Leblanc R.M., Gu Q., Orbulescu J., et al. Photothermal ablation of amyloid aggregates by gold nanoparticles. Colloids Surf B Biointerfaces 2008, 63:200-208.
81. Kolosnjaj J., Szwarc H., Moussa F. Toxicity studies of fullerenes and derivatives. Adv Exp Med Biol 2007, 620:168-180.
82. Vajkoczy P., Laschinger M., Engelhardt B. Integrin-VCAM-1 binding mediates G protein-independent capture of encephalitogenic T cell blasts to CNS white matter microvessels. J Clin Invest 2001, 108:557-565.
83. Carrithers M.D., Visintin I., Kang S.J., Janeway C.A. Differential adhesion molecule requirements for immune surveillance and inflammatory recruitment. Brain 2000, 123:1092-1101.
84. Kanwar J.R., Kanwar R.K., Krissansen G.W. Simultaneous neuroprotection and blockade of inflammation reverses autoimmune encephalomyelitis. Brain 2004, 127:1313-1331.
85. Wang C.X., Huang L.S., Hou L.B., Jiang L., Yan Z.T., Wang Y.L., et al. Antitumor effects of polysorbate-80 coated gemcitabine polybutylcyanoacrylate nanoparticles in vitro and its pharmacodynamics in vivo on C6 glioma cells of a brain tumor model. Brain Res 2009, 19:91-99.
86. Pignatello R., Bucolo C., Ferrara P., Maltese A., Puleo A., Puglisi G. Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur J Pharm Sci 2002, 16:53-61.
87. Kassem M.A., AbdelRahman A.A., Ghorab M.M., Ahmed M.B., Khalil R.M. Nanosuspensions as an ophthalmic delivery system for certain glucocorticoid drugs. Int J Pharm 2007, 340:126-133.
88. Roy I., Stachowiak M.K., Bergey E.J. Non-viral gene transfection nanoparticles: function and applications in the brain. Nanomed Nanotechnol Biol Med 2008, 4:89-97.
89. Peng H., Moffett J., Myers J., Fang X., Stachowiak E.K., Maher P. Novel nuclear signaling pathway mediates activation of fibroblast growth factor-2 gene by type 1 and type 2 angiotensin II receptors. Mol Biol Cell 2001, 12:449-462.
90. Corso T.D., Torres G., Goulah C., Roy I., Gambino A.S., Nayda J. Transfection of tyrosine kinase deleted FGF receptor-1 into rat brain substantia nigra reduces the number of tyrosine hydroxylase expressing neurons and decreases concentration levels of striatal dopamine. Brain Res Mol Brain Res 2005, 139:361-366.
91. Klausner E.A., Zhang Z., Chapman R.L., Multack R.F., Volin M.V. Ultrapure chitosan oligomers as carriers for corneal gene transfer. Biomaterials 2010, 31:1814-1820.
92. Park K., Chen Y., Hu Y., Mayo A.S., Kompella U.B., Longeras R., et al. Nanoparticle-mediated expression of an angiogenic inhibitor ameliorates ischemia-induced retinal neovascularisation and diabetes-induced retinal vascular leakage. Diabetes 2009, 58:1902-1913.
93. Boniou A., Mahajan S.D., Ye L., Kumar R., Ding H., Yong K.T., et al. MMP-9 gene silencing by a quantum dot-siRNA nanoplex delivery to maintain the integrity of the blood brain barrier. Brain Res 2009, 1282:142-155.
94. Gao D., Agayan R.R., Xu H., Philbert M.A., Kopelman R. Nanoparticles for two-photon photodynamic therapy in living cells. Nano Lett 2006, 6:11.
95. Labib A., Lenaerts V., Chouinard F., Leroux J.C., Ouellet R., van Lier J.E. Biodegradable nanospheres containing phthalocyanines and naphthalocyanines for targeted photodynamic tumor therapy. Pharm Res 1991, 8:1027-1031.
96. Gamaleia N.F., Shishko E.D., Dolinsky G.A., Shcherbakov A.B., Usatenko A.V., Kholin V.V. Photodynamic activity of hematoporphyrin conjugates with gold nanoparticles. experiments in vitro. Exp Oncol 2010, 32:44-47.
97. Petry K.G., Boiziau C., Dousset V., Brochet B. Magnetic resonance imaging of human brain macrophage infiltration. Neurotherapeutics 2007, 4:434-442.
98. Yun W., Qing-Cheng L., Lei Y., Jia-Yin M. Mucosal tolerance to E-selectin provides protection against cerebral ischaemia-reperfusion injury in rats. J Neuroimmunol 2008, 205:73-79.
99. Zhang J., Atay T., Nurmikko A.V. Optical detection of brain cell activity using plasmonic gold nanoparticles. Nano Lett 2009, 9:519-524.
100. Lapotko D. Plasmonic nanoparticle-generated photothermal bubbles and their biomedical applications. Nanomedicine (Lond.) 2009, 4:813-845.
101. Cole J.R., Mirin N.A., Knight M.W., Goodrich G.P., Halas N.J. Photothermal efficiencies of nanoshells and nanorods for clinical therapeutic applications. J Phys Chem C 2009, 113:12090-12094.
102. Pankhurst Q.A., Connolly J., Jones S.K., Dobson J. Applications of magnetic nanoparticles in biomedicine. J Phys D Appl Phys 2003, 36:167-181.
103. Jordan A., Maier-Hauff K. Magnetic nanoparticles for intracranial thermotherapy. J Nanosci Nanotechnol 2007, 7:4604-4606.
104. Simkó M., Fiedeler U., Gazsó A., Nentwich M. Einfluss von Nanopartikeln auf zelluläre Funktionen. NanoTrust-Dossiers 2008, 007:1-4.
105. Gopalakrishnan A, Natarajan A, Agarwal A, Sanchan MD, Subramanya GS, Kumar VV. Magneto hyperthermia and cancer therapy. p. 1-23. Available from: http://www.dstuns.iitm.ac.in/teaching-and-presentations/teaching/undergraduate%20courses/vy305-molecular-architecture-and-evolution-of-functions/presentations/presentations-2007/seminar-1/P5.pdf.
106. Xing Y., Xia Z., Rao J. Semiconductor quantum dots for biosensing and in vivo imaging. IEEE Trans Nanobiosci 2009, 8:4-13.
107. Seil J.T., Webster T.J. Decreased astroglial cell adhesion and proliferation on zinc oxide polyurethane composites. Int J Nanomed 2008, 3:523-531.
108. Maojo V., Kulikowski C. Medical informatics and bioinformatics: integration or evolution through scientific crises?. Methods Inf Med 2006, 45:474-482.
109. Altman R.B., Balling R., Brinkley J.F., Coiera E., Consorti F., Dhansay M.A., et al. Commentaries on "Informatics and medicine: from molecules to populations". Methods Inf Med 2008, 47:296-317.
110. Maojo V., Martin-Sanchez F., Kulikowski C., Rodriguez-Paton A., Fritts M. Nanoinformatics and DNA-based computing: catalyzing nanomedicine. Pediatr Res 2010, 67:481-489.
111. De La Iglesia D., Chiesa S., Kern J., Maojo V., Martin-Sanchez F., Potamias G., et al. Nanoinformatics: new challenges for biomedical informatics at the nano level. Stud Health Technol Inform 2009, 150:987-991.
112. Morse T.M. Neuroinformatics: from bioinformatics to databasing the brain. Bioinform Biol Insights 2008, 2:253-264.
113. The Australia and New Zealand Multiple Sclerosis Genetics Consortium. Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. 2009;41:824-8.
114. De Meyer G., Shapiro F., Vanderstichele H., Vanmechelen E., Engelborghs S. De Deyn PP, et al.; for the Alzheimer's Disease Neuroimaging Initiative. Diagnosis-independent alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol 2010, 67:949-956.
115. Nel A., Xia T., Madler L., Li N. Toxic potential of materials at the nanolevel. Science 2006, 311:622-627.
116. Greene L.A., Tischler A.S. Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci USA 1976, 73:2424-2428.
117. Pisanic T.R., Blackwell J.D., Shubayev V.I., Fiñones R.R., Jin S. Nanotoxicity of iron oxide nanoparticle internalization in growing neurons. Biomaterials 2007, 28:2572-2581.
118. Hussain S.M., Javorina A.K., Schrand A.M., Duhart H.M., Ali S.F., Schlager J.J. The interaction of manganese nanoparticles with PC-12 cells induces dopamine depletion. Toxicol Sci 2006, 92:456-463.
119. Wang J., Rahman M.F., Duhart H.M., Newport G.D., Patterson T.A., Murdock R.C., et al. Expression changes of dopaminergic system-related genes in PC12 cells induced by manganese, silver, or copper nanoparticles. Neurotoxicology 2009, 30:926-933.
120. Deng X., Luan Q., Chen W., Wang Y., Wu M., Zhang H., et al. Nanosized zinc oxide particles induce neural stem cell apoptosis. Nanotechnology 2009, 20:115101.
121. Kim Y.S., Kim J.S., Cho H.S., Rha D.S., Kim J.M., Park J.D., et al. Twenty-eight day oral toxicity, genotoxicity, and gender-related tissue distribution of silver nanoparticles in Sprague-Dawley rats. Inhal Toxicol 2008, 20:575-583.
122. Kircher M.F., Mahmood U., King R.S., Weissleder R., Josephson L. A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res 2003, 63:8122-8125.
123. Hans L., Lowman A. Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mater Sci 2002, 6:319-327.
124. Shirahama H., Yasuda H. Biodegradable Pasties and Polymers. Proceedings of the Third International Scientific Workshop on Biodegradable Plastics and Polymers, Osaka Japan (Studies in Polymer Science) 1994, 541. Elsevier, Amsterdam. 3rd ed. Y. Doi, K. Fukuda (Eds.).
125. Kitano H. Computational systems biology. Nature 2002, 420:206-210.
126. Ankola D.D., Durbin E.W., Buxton G.A., Schäfer J., Bakowsky U., Kumar M.N. Preparation, characterization and in silico modeling of biodegradable nanoparticles containing cyclosporine A and coenzyme Q10. Nanotechnology 2010, 21:065104.
127. Giugliano M., Prato M., Ballerini L. Nanomatrial/neuronal hybrid system for functional recovery of the CNS. Drug Discov Today 2008, 5:37-43.
128. Carnevale N.T., Hines M.L. The neuron 2006, Cambridge Univ. Press, Cambridge, UK.
129. Frieboes H.B., Sinek J.P., Nalcioglu O., Fruehauf J.P., Cristini V. Nanotechnology in cancer drug therapy: a biocomputional approach. BioMES and biomedical nanotechnology 2006, 435-460. Springer Publications, New York, NY. M. Ferrari, A.P. Lee, L.J. Lee (Eds.).
130. Cachau R.E., Gonzalez-Nilo F.D., Ventura O., Fritts M. In silico nanobio-design. a new frontier in computational biology. Curr Top Med Chem 2007, 7:1537-1540.
131. Rami A., Bechmann I., Stehle J.H. Exploiting endogenous antiapoptotic proteins for novel therapeutic strategies in cerebral ischemia. Prog Neurobiol 2008, 85:273-296.
132. Baratchi S., Kanwar R.K., Antonio Cheung C.H., Kanwar J.R. Proliferative and protective effects of SurR9-C84A on differentiated neural cells. J Neuroimmunol 2010, 227:120-132.
133. Baratchi S., Kanwar R.K., Kanwar J.R. Survivin mutant protects differentiated dopaminergic SK-N-SH cells against oxidative stress. PLoS ONE 2011, 6:e15865.
134. Singh S.K., Koshkin A.A., Wengel J., Nielsen P. LNA (locked nucleic acids): synthesis and high affinity nucleic acid recognition. Chem Commun 1998, 455-456.
135. Veedu R.N., Wengel J. Locked nucleic acids: promising nucleic acid analogs for therapeutic applications. Chem Biodivers 2010, 7:536-542.
136. Wengel J. Synthesis of 3'-C- and 4'-C- branched oligonucleotides and the development of locked nucleic acid (LNA). Acc Chem Res 1999, 32:301-310.